Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | CDC42 | P60953 | 1/20 | 0.97 |
| ▸ | RAC1 | P63000 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL2472354 | 1.00 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28999051 | 1.00 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3832769 | 0.98 | AKR1C3 (0.94) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19456 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-12605348-B2 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | CATALENT ONTARIO LIMITED (CA) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260074073-A1 | Biomarker for Seronegative Rheumatoid Arthritis | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2026-03-12 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| EP-4694876-A2 | SULFONAMIDES WITH ACTIVITY IN ACUTE KIDNEY INJURY AND FIBROSIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260021064-A1 | ACETAMINOPHEN AND NAPROXEN FOR TREATING PAIN | KENVUE BRANDS LLC (US) | 2026-01-22 | — | — | US | claimed |
| US-20260007606-A1 | NAPROXEN SODIUM TABLETS PRODUCED USING A CONTINUOUS PROCESS | BAYER HEALTHCARE LLC (US) | 2026-01-08 | — | — | US | claimed |
| US-20260000772-A1 | NONSTEROIDAL ANTI-INFLAMMATORY DRUG COMPLEXES AND METHODS OF MAKING AND USING | ARECA BSC DEV LLC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250387488-A1 | ACTIVE AGENT-ELUTING HEMOSTATIC AGENTS AND METHODS OF USE THEREOF | FLORIDA SOUTHERN COLLEGE (US) | 2025-12-25 | — | — | US | claimed |
| EP-0456988-A2 | Use of naproxen as mydriatic agent | S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. (IT) | 1991-11-21 | — | — | EP | claimed |
| US-5043167-A | Galenic formulations with programmed release | ALFA WASSERMANN S.P.A. (IT) | 1991-08-27 | — | — | US | claimed |
| EP-0436373-A1 | Process for making tablets containing spray-dried naproxen or naproxen sodium | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1991-07-10 | — | — | EP | claimed |
| EP-0324981-A1 | New galenic formulations with programmed release | ALFA WASSERMANN S.p.A. (IT) | 1989-07-26 | — | — | EP | claimed |
| US-4803079-A | ORAL ADMINISTRATION; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-02-07 | — | — | US | claimed |
| EP-0227814-A1 | THERAPEUTIC FORMULATIONS WITH BIMODAL RELEASE CHARACTERISTICS | THE UPJOHN COMPANY (US) | 1987-07-08 | — | — | EP | claimed |
| WO-1987000044-A1 | THERAPEUTIC FORMULATIONS WITH BIMODAL RELEASE CHARACTERISTICS | THE UPJOHN COMPANY (US) | 1987-01-15 | — | — | WO | claimed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | claimed |
| US-4571333-A | IN HYDROXYPROPYLMETHYL CELLULOSE MATRIX | SYNTEX (U.S.A.) INC. (US) | 1986-02-18 | — | — | US | claimed |
| EP-0159852-A2 | Directly compressible pharmaceutical compositions | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-10-30 | — | — | EP | claimed |